Claims

1. A nasal pharmaceutical composition which comprises
(a) at least one active substance suitable for nasal administration,
(b) a mucopolysaccharide, and
(c) propylene glycol.

2. A composition according to claim 1, wherein the active substance (a) is selected from the group of vasoconstrictors consisting of xylometazoline, naphazoline, fenoxazoline, oxymetazoline, tetrahydrozoline, tramazoline, phenylephrine, ephedrine, epinephrine, and nasally acceptable salts of any of these compounds.

3. A composition according to claim 1, wherein the active substance (a) is xylometazoline or a nasally acceptable salt thereof.

4. A composition according to any one of claims 1-3, wherein the mucopolysaccharide (b) is selected from the group consisting of chondroitin, hyaluronic acid, dermatan, keratan, heparin, acemannan, and nasally acceptable salts of any of said compounds.

5. A composition according to any one of claims 1-4, wherein the mucopolysaccharide (b) is chondroitin sulfate.

6. A composition according to any one of claims 1-5, wherein the propylene glycol (c) is present in an amount of from 1 up to 5 % (w/w) of the total composition.

7. A composition according to any one of claims 1-6, which includes water as vehicle.

8. A composition according to any one of claims 1-7, which in addition includes a nasally acceptable film-forming agent.

9. A composition according to any one of claims 1-8, which in addition includes an essential oil of a plant.

10. A composition according to any one of claims 1-9, which in addition includes a nasally acceptable preservative.

11. A composition according to any one of claims 1-9, which is devoid of an additional nasally acceptable preservative.

12. A nasal pharmaceutical composition which consists essentially of
(a) at least one active substance suitable for nasal administration,
(b) a mucopolysaccharide,
(c) propylene glycol, and
water.

13. A nasal pharmaceutical composition which consists essentially of
(a) at least one active substance suitable for nasal administration,
(b) a mucopolysaccharide,
(c) propylene glycol,
a nasally acceptable preservative, and
water.

14. A nasal pharmaceutical composition which consists of
(a) at least one active substance suitable for nasal administration,
(b) a mucopolysaccharide,
(c) propylene glycol,
water, and
nasally acceptable excipients.

15. A nasal pharmaceutical composition which consists of
(a) at least one active substance suitable for nasal administration,
(b) a mucopolysaccharide,
(c) propylene glycol,
a nasally acceptable preservative,
water, and
nasally acceptable excipients.

16. A nasal pharmaceutical composition according to anyone of claims 12-15, wherein the mucopolysaccharide (b) is selected from the group consisting of chondroitin, hyaluronic acid, dermatan and nasally acceptable salts of any of said compounds.

17. A composition according to any one of claims 1-16, which is in the form of drops, a solution, a spray or a metered-dose spray.